Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's strong management team and innovative drug pipeline focused on challenging RAS targets [1] Group 1: Product Pipeline and Innovation - The company has developed a diversified product pipeline centered around the difficult-to-drug RAS family members, leveraging deep understanding and successful R&D experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [2] - The product pipeline extends beyond RAS targets to include other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting market opportunities with favorable competitive landscapes [2] Group 2: Clinical Data and Competitive Advantage - The competitive advantage in RAS-targeted drug development is evident in the clinical data for GFH925 and GFH375, with GFH925 showing superior efficacy in 2L+ KRASG12C mutation NSCLC compared to overseas competitors and comparable or better results against domestic rivals [3] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, with promising preliminary data in third-line pancreatic cancer [3] - The dual antibody GDF15/IL-16 (GFS202A) shows early advantages in tolerability and activity compared to single-target drugs [3] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [4] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [4] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in China and overseas collaboration for GFH375 [5] - Based on a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x revenue peak sales multiple and an 87% potential upside [5] - Future focus includes monitoring the sales ramp-up of GFH925 post-reimbursement inclusion and additional data readouts from the RAS pipeline [5]